Canaccord initiated coverage of Nuvalent (NUVL) with a Buy rating and $126 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $120 from $105 at Goldman Sachs
- Nuvalent price target raised to $132 from $114 at UBS
- Nuvalent’s Promising Drug Pipeline and Strong Financials Make It a Buy
- Nuvalent price target raised to $112 from $100 at Barclays
- Nuvalent, Inc. Reports Q3 2025 Progress and Financials